MyMD Pharmaceuticals Files 8-K
Ticker: QCLS · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
TL;DR
MyMD Pharma filed an 8-K on March 5th for disclosures and financials.
AI Summary
MyMD Pharmaceuticals, Inc. filed an 8-K on March 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Akers Biosciences, Inc., is incorporated in Delaware and headquartered in Baltimore, MD.
Why It Matters
This filing indicates updates regarding company disclosures and financial statements, which are important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing for disclosures and financial statements, not indicating any immediate significant operational or financial changes.
Key Numbers
- 001-36268 — Commission File Number (SEC file number for MyMD Pharmaceuticals, Inc.)
- 22-2983783 — IRS Employer Identification No. (Tax identification number for MyMD Pharmaceuticals, Inc.)
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- Akers Biosciences, Inc. (company) — Former company name
- March 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Baltimore, MD (location) — Address of principal executive offices
FAQ
What specific event triggered this 8-K filing?
The 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on March 5, 2024.
What is the current name of the company filing this report?
The current name of the company is MyMD Pharmaceuticals, Inc.
What were the former names of MyMD Pharmaceuticals, Inc.?
The company was formerly known as Akers Biosciences, Inc.
Where is MyMD Pharmaceuticals, Inc. headquartered?
MyMD Pharmaceuticals, Inc. is headquartered at 855 N. Wolfe Street, Suite 601, Baltimore, MD 21205.
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-05 11:00:19
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 13KB
- 0001493152-24-008824.txt ( ) — 223KB
- mymd-20240305.xsd (EX-101.SCH) — 3KB
- mymd-20240305_lab.xml (EX-101.LAB) — 33KB
- mymd-20240305_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: March 5, 2024 By: /s/ Chris Chapman Chris Chapman, M.D. President